Flagship co-founded Epitome Biosystems in 2003 to commercialize multiplex protein detection technologies licensed from engeneOS Corp. The company’s technology employs proprietary arrays that allow for highly precise, parallel protein analyses in biological samples by using unique signature peptides to fingerprint the proteome. This tackles the problem of protein content which has been limiting the protein array market to date. Industry veteran, President Neal Gordon, leads the management team. Ed Kania is a Director along with Prof. Daniel Wang, Institute Professor at MIT.

www.epitomebiosystems.com